Blog
RSS FeedPosted by Michael Wonder on 07 Jan 2022
NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer
7 January 2022 - With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer ...
Posted by Michael Wonder on 26 Dec 2021
Children and young people set to benefit from new treatment for peanut allergy
23 December 2021 - Children and young people aged between 4 and 17 with a peanut allergy could be set to ...
Posted by Michael Wonder on 16 Dec 2021
NICE recommend venetoclax and azacitidine for patients with aggressive blood cancer
16 December 2021 - Venetoclax is an oral once daily treatment, which blocks the action of the B-cell lymphoma-2 protein, ...
Posted by Michael Wonder on 16 Dec 2021
NICE recommends offering PrEP to people at high risk of HIV for first time
15 December 2021 - People at the highest risk of catching HIV should be offered pre-exposure prophylaxis, NICE has recommended for ...
Posted by Michael Wonder on 15 Dec 2021
NICE finally accepts use of rare cancer therapy Poteligeo
15 December 2021 - NICE has reversed its earlier decision not to recommend the use of Kyowa Kirin’s Poteligeo (mogamulizumab). ...
Posted by Michael Wonder on 09 Dec 2021
NICE publish final guidance recommending Aspaveli in adults with ultra rare blood disorder
9 December 2021 - The medicine is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a ...
Posted by Michael Wonder on 08 Dec 2021
NICE terminates appraisal of yet another cancer medicine
7 December 2021 - NICE is unable to make a recommendation on the use of olaparib (Lynparza) on the NHS for ...
Posted by Michael Wonder on 01 Dec 2021
NICE terminates appraisal of new treatment for adolescents with obesity
1 December 2021 - NICE is unable to make a recommendation on liraglutide (Saxenda) for managing obesity in adolescents aged 12 ...
Posted by Michael Wonder on 30 Nov 2021
Over 600 people set to benefit from innovative lung cancer treatment within the Cancer Drugs Fund
30 November 2021 - More than 600 people could benefit from an innovative drug for a form of lung cancer ...
Posted by Michael Wonder on 29 Nov 2021
NICE publishes draft guidance on new medicine for osteoporosis
25 November 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using romosozumab in ...
Posted by Michael Wonder on 20 Nov 2021
NICE recommends Inrebic for rare blood cancer
19 November 2021 - NICE have issued a final appraisal determination recommending the use of Inrebic (fedratinib) on the NHS for ...
Posted by Michael Wonder on 20 Nov 2021
NICE draft guidance recommends new treatment for spinal muscular atrophy as part of a managed access agreement
19 November 2021 - Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit ...
Posted by Michael Wonder on 20 Nov 2021
NICE approves first long-acting injectable HIV-1 treatment
18 November 2021 - NICE has today published draft guidance recommending the first long-acting injectable treatment for HIV-1 infection in adults. ...
Posted by Michael Wonder on 16 Nov 2021
Are we measuring what matters most on uptake to medicines in England?
16 November 2021 - VPAS is a voluntary agreement between the UK government and the Association of the British Pharmaceutical ...
Posted by Michael Wonder on 15 Nov 2021
NICE recommends cenobamate for treatment of adult epilepsy patients in UK
15 November 2021 - NICE has issued a positive recommendation for Arvelle Therapeutics’ cenobamate (Ontozry), for the treatment of focal-onset ...